3.89
-0.15(-3.71%)
Currency In USD
| Previous Close | 4.04 |
| Open | 4.06 |
| Day High | 4.26 |
| Day Low | 3.88 |
| 52-Week High | 16.11 |
| 52-Week Low | 3.83 |
| Volume | 440,377 |
| Average Volume | 349,255 |
| Market Cap | 176.13M |
| PE | -5.81 |
| EPS | -0.67 |
| Moving Average 50 Days | 4.68 |
| Moving Average 200 Days | 9.44 |
| Change | -0.15 |
If you invested $1000 in Y-mAbs Therapeutics, Inc. (YMAB) since IPO date, it would be worth $162.08 as of May 12, 2025 at a share price of $3.89. Whereas If you bought $1000 worth of Y-mAbs Therapeutics, Inc. (YMAB) shares 5 years ago, it would be worth $102.1 as of May 12, 2025 at a share price of $3.89.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)
GlobeNewswire Inc.
May 07, 2025 11:05 AM GMT
PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and an
Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025
GlobeNewswire Inc.
May 06, 2025 11:05 AM GMT
PRINCETON, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and an
Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting
GlobeNewswire Inc.
Apr 27, 2025 7:00 PM GMT
NEW YORK, April 27, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibod